Abstract: Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.

Abstract: A photovoltaic assembly includes a first cover plate, a first adhesive film, a solar cell layer, a second adhesive film, and a second cover plate that are stacked in sequence. The first cover plate is provided on a light-facing surface of the photovoltaic assembly. A first pad strip is provided between the first cover plate and the first adhesive film. The first pad strip covers a long edge region, a short edge region, and a middle strip region of the first adhesive film. A second pad strip is provided between the solar cell layer and the second adhesive film. The second pad strip covers a short edge region of the second adhesive film.

Abstract: Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.

Abstract: Provided herein are methods of treating a skin-related disease or disorder (such as melasma). Also provided are pharmaceutical compositions of midostaurin or a pharmaceutically acceptable salt thereof formulated for topical administration. Further described are methods for preparing such topical pharmaceutical compositions and methods of using the same for treating a subject.

Abstract: Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional degraders that specifically eliminate targeted proteins by hijacking the ubiquitin-proteasome system (UPS). Provided are pharmaceutical compositions which include a mixture of a PROTAC, a hydrophilic polymer, a surfactant, and optionally an acid and an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising PROTAC.

Abstract: Provided are pharmaceutical compositions which include an amorphous solid dispersion comprising i) a lipophilic active pharmaceutical ingredient such as abiraterone, alectinib, pazopanib, cabozantinib, venetoclax, lurasidone, or vilazodone or a salt thereof, ii) a hydrophilic polymer, iii) optionally a surfactant, iv) optionally an adsorbent, and v) optionally an acid. Also described are methods for preparing such pharmaceutical compositions and treating a subject in need thereof. In one aspect, disclosed herein is an amorphous solid dispersion comprising an active pharmaceutical ingredient.

Abstract: Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional degraders that specifically eliminate targeted proteins by hijacking the ubiquitin-proteasome system (UPS). Provided are pharmaceutical compositions which include a mixture of a PROTAC, a hydrophilic polymer, a surfactant, and optionally an acid and an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising PROTAC.

Abstract: Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.

Abstract: A photovoltaic module includes a first sealing member, a pad strip, a solar cell string, and a second sealing member. A cross-linking rate of a material of the second sealing member is higher than that of a material of the first sealing member. The first sealing member, the solar cell string, and the second sealing member are sequentially arranged along a thickness direction of the photovoltaic module. The pad strip is located around the solar cell string and located between the first sealing member and the second sealing member. The pad strip is made of a same material as the first sealing member. A thickness of the first sealing member, a thickness of the second sealing member, and a thickness of the pad strip all gradually decrease along a length direction of the photovoltaic module towards an edge of the photovoltaic module.

Abstract: An amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

Abstract: Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.

Abstract: An amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

Abstract: Provided are pharmaceutical compositions which include a mixture of a lipophilic active pharmaceutical ingredient such as nilotinib, a hydrophilic polymer, one or more surfactants, and optionally an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising the active pharmaceutical ingredient.

Abstract: Proteolysis Targeting Chimeras (PROTACs) are heterobifunctional degraders that specifically eliminate targeted proteins by hijacking the ubiquitin-proteasome system (UPS). Provided are pharmaceutical compositions which include a mixture of a PROTAC, a hydrophilic polymer, a surfactant, and optionally an acid and an adsorbent. Also described are methods for preparing and using such pharmaceutical compositions. In one aspect, disclosed herein is an amorphous solid dispersion comprising PROTAC.

Abstract: Provided are pharmaceutical compositions which include an active pharmaceutical ingredient having a calculated log P in octanol-water equal or greater than about 4.0, at least one solubilizer, and optionally at least one stratum corneum penetration enhancer, wherein the pharmaceutical composition can be formulated for topical administration. In some instances, the active pharmaceutical ingredient is clofazimine.

Abstract: Provided are amorphous solid dispersions comprising an active pharmaceutical ingredient and pharmaceutical compositions comprising the amorphous solid dispersions. Also described herein are methods for preparing and using such compositions. In some embodiments, an amorphous solid dispersion comprises an active pharmaceutical ingredient such as palbociclib or neratinib, one or more acids, and a high-molecular weight material.

Abstract: Provided are pharmaceutical compositions which comprise a mixture of a lipophilic active pharmaceutical ingredient, at least one long chain fatty acid or at least one fatty acid glyceride, a surfactant, and optionally an antioxidant. Also described are methods for preparing and using such pharmaceutical compositions. The active pharmaceutical ingredient in such a combination has improved bioavailability compared to the active pharmaceutical ingredient alone.